Dr. Thomas Walters Presents Update on Nicox’s NCX 470 Phase 2 Clinical Study in Podium Presentation at ASCRS 2019

Press Release
Dr. Thomas Walters Presents Update on Nicox’s NCX 470 Phase 2 Clinical Study in Podium Presentation at ASCRS 2019
  • Enrollment rate now at 90%
  • Key Opinion Leader endorsement of the potential for NCX 470 in intraocular pressure (IOP) lowering
May 6, 2019 – release at 7:30 am CET
Sophia Antipolis, France


Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that ophthalmology key opinion leader and clinical investigator in the ongoing NCX 470 Phase 2 clinical study Dr. Thomas Walters MD delivered a podium presentation at the annual meeting of the American Society of Cataract and Retinal Surgery (ASCRS) 2019 in San Diego updating on the progress of the NCX 470 Phase 2 clinical study in patients with glaucoma or ocular hypertension.

The presentation highlighted that the 420-patient study, which started in August 2018, was progressing well, having reached 90% enrollment.  The presentation also highlighted the potential for NCX 470 to become the best-in-class first line therapy for lowering intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.

NCX 470 is a novel, second-generation nitric oxide (NO)-donating prostaglandin analog which is currently in a multicenter, U.S. Phase 2 clinical study for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension.  Top-line data is expected in Q4 of this year

ASCRS 2019 took place from May 3-May 7, 2019 in San Diego, United States. The presentation was entitled Site Initiation Rates and Subject Enrollment Rates for 28-Day, First-in-Human Phase 2 Clinical Study of NCX 470: Novel NO-Donating Bimatoprost Analog.
About Nicox
Nicox S.A. is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health.  By leveraging our proprietary expertise in nitric oxide (NO) donation and other technologies, we are developing an extensive portfolio of novel product candidates that target multiple ophthalmic conditions, including glaucoma.  Our portfolio includes three programs in development including NCX 470 for intraocular pressure lowering, based on our proprietary NO-donating research platform and NCX 4251, a proprietary formulation of the well-established molecule fluticasone, for acute exacerbations of blepharitis.  Our research activities are focused on novel future generation NO-donors including NO-donating phosphodiesterase-5 (PDE5) inhibitors and NO-donating soluble guanylate cyclase (sGC) stimulators (in partnership with Ironwood).  In addition, we have two ophthalmology assets that have been approved by the U.S. Food and Drug Administration (FDA); VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024%, exclusively licensed worldwide to Bausch + Lomb, a Bausch Health Companies Inc. company, and commercialized in the U.S. by Bausch + Lomb since December 2017, as well as ZERVIATE™ (cetirizine ophthalmic solution), 0.24%, exclusively licensed in the U.S. to Eyevance Pharmaceuticals, LLC. 

Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes.

For more information on Nicox, its products or pipeline, please visit: www.nicox.com.
Analyst coverage
Bryan, Garnier & Co   Hugo Solvet   Paris, France
H.C. Wainwright & Co Yi Chen  New York, U.S.

The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.
Upcoming financial and business conferences

May 16  European MidCap Event    Copenhagen, Denmark 
June 2-6  BIO 2019    Philadelphia, U.S.
June 18-19  European MidCap Event  Paris, France
June 19-20  JMP Securities Healthcare Conference  New York, U.S.
June 24-25   HealthTech Investor Day  Paris, France
Gavin Spencer
Executive Vice President, Chief Business Officer
& Head of Corporate Development  
T +33 (0)4 97 24 53 00
Investors & Media
United States & Europe
LifeSci Advisors, LLC
Hans Herklots
T +41 79 598 71 49  
LifeSci Advisors, LLC
Sophie Baumont
M +33 (0)6 27 74 74 49
The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.

Risks factors which are likely to have a material effect on Nicox’s business are presented in the 4th chapter of the ‘Document de référence, rapport financier annuel et rapport de gestion 2018’ filed with the French Autorité des Marchés Financiers (AMF) on March 6, 2019 which are available on Nicox’s website (www.nicox.com).
Nicox S.A.
Drakkar 2
Bât D, 2405 route des Dolines
CS 10313, Sophia Antipolis
06560 Valbonne, France
T +33 (0)4 97 24 53 00
F +33 (0)4 97 24 53 99